IND Amendment Clearance Obtained for Clinical Manufacturing of Rese-Cel from Cabaletta Bio Using Cellares' Automated PlatformsBusiness Wire • 01/12/26
Cabaletta Bio, Inc. (CABA) Presents at Citi Annual Global Healthcare Conference 2025 TranscriptSeeking Alpha • 12/03/25
Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 11/10/25
Cabaletta Bio to Participate in Upcoming Investor Conferences in November and DecemberGlobeNewsWire • 11/04/25
Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025GlobeNewsWire • 10/27/25
Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement GrantGlobeNewsWire • 10/14/25
Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual CongressGlobeNewsWire • 10/09/25
Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 08/07/25
What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?Benzinga • 07/30/25
Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 CongressGlobeNewsWire • 06/11/25
Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational CohortsGlobeNewsWire • 05/15/25
Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 03/31/25
Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle™ PlatformBusiness Wire • 03/19/25
Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care ConferenceGlobeNewsWire • 02/26/25
UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific MeetingsGlobeNewsWire • 02/18/25
Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific MeetingsGlobeNewsWire • 02/18/25
Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in FebruaryGlobeNewsWire • 02/11/25